Nexalis Therapeutics’ two clinical studies exploring inhaled cannabinoid treatments for breakthrough cancer pain and panic disorder […]
Nexalis Trials Stay Frozen as $53m Rescue Deal Falls Apart
The Cannabis Observer
·
FOUNDING MEMBERS
First 100 readers lock in 50% off for life
Sector coverage written for operators, not tourists. Reserve founding-member pricing before launch.
- Weekday briefings on regulation, access schemes, and the companies shaping the market
- Full archive and weekly deep-dives once premium goes live
- 50% off the launch price, locked in for as long as your subscription stays active
Join 87 readers already on the waitlist
ASX
biotechnology
Breakthrough cancer pain
funding
IRX-211
IRX-616a
Nexalis Therapeutics
NX1
panic disorder